These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24753184)

  • 1. The TP53 gene network in a postgenomic era.
    Soussi T
    Hum Mutat; 2014 Jun; 35(6):641-2. PubMed ID: 24753184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
    Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.
    Eischen CM; Lozano G
    Hum Mutat; 2014 Jun; 35(6):728-37. PubMed ID: 24488925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disrupting TP53 in mouse models of human cancers.
    Parant JM; Lozano G
    Hum Mutat; 2003 Mar; 21(3):321-6. PubMed ID: 12619119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.
    Riemenschneider MJ; Büschges R; Wolter M; Reifenberger J; Boström J; Kraus JA; Schlegel U; Reifenberger G
    Cancer Res; 1999 Dec; 59(24):6091-6. PubMed ID: 10626796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics].
    Marine Ch
    Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era.
    Soussi T; Leroy B; Taschner PE
    Hum Mutat; 2014 Jun; 35(6):766-78. PubMed ID: 24729566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
    Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
    Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
    Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
    Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
    Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity.
    Andrysik Z; Galbraith MD; Guarnieri AL; Zaccara S; Sullivan KD; Pandey A; MacBeth M; Inga A; Espinosa JM
    Genome Res; 2017 Oct; 27(10):1645-1657. PubMed ID: 28904012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma.
    Patel H; Polanco-Echeverry G; Segditsas S; Volikos E; McCart A; Lai C; Guenther T; Zaitoun A; Sieber O; Ilyas M; Northover J; Silver A
    Int J Cancer; 2007 Dec; 121(12):2668-73. PubMed ID: 17721920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
    Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
    Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, causes and impact of TP53-loss phenocopying events in human tumors.
    Fito-Lopez B; Salvadores M; Alvarez MM; Supek F
    BMC Biol; 2023 Apr; 21(1):92. PubMed ID: 37095494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
    Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
    Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.